Cargando…
In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma
Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959435/ https://www.ncbi.nlm.nih.gov/pubmed/32002303 http://dx.doi.org/10.1080/2162402X.2019.1708066 |
| _version_ | 1783487597264240640 |
|---|---|
| author | Koster, Bas D. de Jong, Tamarah D. van den Hout, Mari F. C. M. Sluijter, Berbel J. R. Vuylsteke, Ronald J. C. L. M. Molenkamp, Barbara G. Vosslamber, Saskia van den Tol, M. Petrousjka van den Eertwegh, Alfons J. M. de Gruijl, Tanja D. |
| author_facet | Koster, Bas D. de Jong, Tamarah D. van den Hout, Mari F. C. M. Sluijter, Berbel J. R. Vuylsteke, Ronald J. C. L. M. Molenkamp, Barbara G. Vosslamber, Saskia van den Tol, M. Petrousjka van den Eertwegh, Alfons J. M. de Gruijl, Tanja D. |
| author_sort | Koster, Bas D. |
| collection | PubMed |
| description | Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences. |
| format | Online Article Text |
| id | pubmed-6959435 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69594352020-01-30 In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma Koster, Bas D. de Jong, Tamarah D. van den Hout, Mari F. C. M. Sluijter, Berbel J. R. Vuylsteke, Ronald J. C. L. M. Molenkamp, Barbara G. Vosslamber, Saskia van den Tol, M. Petrousjka van den Eertwegh, Alfons J. M. de Gruijl, Tanja D. Oncoimmunology Point-of-View Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences. Taylor & Francis 2019-12-26 /pmc/articles/PMC6959435/ /pubmed/32002303 http://dx.doi.org/10.1080/2162402X.2019.1708066 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Point-of-View Koster, Bas D. de Jong, Tamarah D. van den Hout, Mari F. C. M. Sluijter, Berbel J. R. Vuylsteke, Ronald J. C. L. M. Molenkamp, Barbara G. Vosslamber, Saskia van den Tol, M. Petrousjka van den Eertwegh, Alfons J. M. de Gruijl, Tanja D. In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma |
| title | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma |
| title_full | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma |
| title_fullStr | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma |
| title_full_unstemmed | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma |
| title_short | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma |
| title_sort | in the mix: the potential benefits of adding gm-csf to cpg-b in the local treatment of patients with early-stage melanoma |
| topic | Point-of-View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959435/ https://www.ncbi.nlm.nih.gov/pubmed/32002303 http://dx.doi.org/10.1080/2162402X.2019.1708066 |
| work_keys_str_mv | AT kosterbasd inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT dejongtamarahd inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT vandenhoutmarifcm inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT sluijterberbeljr inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT vuylstekeronaldjclm inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT molenkampbarbarag inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT vosslambersaskia inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT vandentolmpetrousjka inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT vandeneertweghalfonsjm inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma AT degruijltanjad inthemixthepotentialbenefitsofaddinggmcsftocpgbinthelocaltreatmentofpatientswithearlystagemelanoma |